10-K: Kymera Therapeutics Advances Pipeline, Secures Funding

Kymera Therapeutics reports significant progress in its clinical pipeline, including positive Phase 1b results for KT-621 in Atopic Dermatitis, new collaborations, and substantial capital raises, despite continued operating losses.

Summary

• Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on Targeted Protein Degradation (TPD) to develop innovative oral medicines, primarily in immunology and oncology.
• The company's publicly disclosed immunology programs target STAT6 (KT-621), IRF5 (KT-579), and IRAK4 (KT-485/SAR447971).
• KT-621 initiated two parallel Phase 2b clinical trials for moderate to severe Atopic Dermatitis (BROADEN2) and asthma (BREADTH).
• Phase 1b results for KT-621 in moderate to severe Atopic Dermatitis (22 patients) showed deep STAT6 degradation (98% in blood, 94% in skin), significant reductions in Type 2 biomarkers (median TARC 74% in high baseline patients, Eotaxin-3 62-73%, IL-31 54-56%, FeNO 25-33%), and clinical improvements (mean EASI reduction 63%, EASI-50 76%, EASI-75 29%, mean PPNRS reduction 40%, mean SCORAD reduction 48%, mean sleeplessness reduction 76%).
• KT-579, an oral IRF5 degrader, recently initiated a Phase 1 clinical trial in healthy volunteers, supported by strong preclinical data demonstrating high selectivity, picomolar to nanomolar potencies, robust degradation (>90%), and efficacy in lupus and rheumatoid arthritis models.
• Sanofi plans to advance the IRAK4 degrader KT-485/SAR447971 into clinical testing in 2026, while discontinuing development of KT-474.
• A new strategic collaboration with Gilead Sciences was announced in June 2025 to develop novel oral molecular glue degraders for CDK2 in oncology, with Kymera leading research and Gilead holding an exclusive option for global licensing.
• The company reported net losses of $311.4 million for the year ended December 31, 2025, compared to $223.9 million in 2024 and $147.0 million in 2023, resulting in an accumulated deficit of $1,066.0 million as of December 31, 2025.
• Collaboration revenue decreased to $39.2 million in 2025 (Sanofi: $33.6 million, Gilead: $5.6 million) from $47.1 million in 2024, primarily due to the satisfaction of performance obligations under the Sanofi agreement and the expiration of the Vertex agreement.
• Research and development expenses increased to $316.6 million in 2025 from $240.2 million in 2024, driven by increased costs for the STAT6 program and higher employee headcount.
• General and administrative expenses increased to $68.2 million in 2025 from $63.5 million in 2024.
• Cash, cash equivalents, and marketable securities totaled $1,619.4 million as of December 31, 2025, which is expected to fund operations into 2029.
• The company completed follow-on public offerings in June and December 2025, raising approximately $288.4 million and $692.3 million in gross proceeds, respectively.
• An Open Market Sale Agreement with Jefferies LLC for up to $300.0 million in at-the-market offerings was entered into in October 2024, with no sales made as of December 31, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, reflecting strong clinical data for KT-621, promising preclinical results for KT-579, and new strategic collaborations that validate its TPD platform and significantly bolster its cash position, despite continued operating losses typical for a clinical-stage biotech.

Positives

• KT-621 demonstrated strong positive results in its Phase 1b Atopic Dermatitis trial, showing deep STAT6 degradation, significant biomarker reductions, and clinical improvements comparable to or numerically exceeding dupilumab at week 4.
• KT-621 showed initial proof of concept for inhibiting Type 2 inflammation in lungs (FeNO reduction) in Atopic Dermatitis patients with comorbid asthma.
• KT-579 initiated a Phase 1 clinical trial, supported by robust preclinical data indicating high selectivity, potency, and efficacy in lupus and rheumatoid arthritis models.
• A new strategic collaboration with Gilead Sciences for CDK2 molecular glue degraders in oncology includes a $40.0 million upfront payment and potential milestones up to $665.0 million, validating the TPD platform and diversifying the pipeline.
• Sanofi's decision to advance KT-485/SAR447971 into clinical testing in 2026 indicates continued confidence in the IRAK4 degrader program.
• The company maintains a strong financial position with $1,619.4 million in cash, cash equivalents, and marketable securities as of December 31, 2025, providing a projected operational runway into 2029.
• Successful capital raises through follow-on public offerings in 2025 significantly bolstered the company's financial resources.
• Management concluded that internal control over financial reporting was effective as of December 31, 2025.

Negatives

• The company continues to incur significant operating losses, with net losses of $311.4 million in 2025, $223.9 million in 2024, and $147.0 million in 2023.
• An accumulated deficit of $1,066.0 million as of December 31, 2025, reflects the substantial investment in research and development without product sales revenue.
• Sanofi discontinued the development of KT-474 (IRAK4) to prioritize KT-485, indicating a setback for the former program.
• The strategic decision was made in May 2025 not to advance KT-295 (TYK2) into further clinical development.
• Collaboration revenue decreased in 2025 due to the satisfaction of a performance obligation under the Sanofi agreement and the expiration of the Vertex agreement.
• Impairment of long-lived assets totaling $3.9 million in 2025 and $4.9 million in 2024 resulted from exiting the 2019 Lease facility.
• The company is a clinical-stage entity with no approved products, making future profitability highly uncertain and dependent on successful drug development and commercialization.

Risks

• As a clinical-stage company, evaluating the success of the business to date and assessing future viability is difficult for stockholders.
• Significant operating losses have been incurred since inception, and continued losses are anticipated for the foreseeable future.
• Substantial additional funding will be required; inability to raise capital when needed or on attractive terms could force delays or discontinuation of development programs.
• Product candidates are in early clinical development, and failure to advance them through the clinic or commercialize them, or significant delays, would materially harm the business.
• The novel and unproven approach of targeted protein degradation makes it difficult to predict the time, cost, and likelihood of successfully developing any products.
• There is a risk of expending limited resources to pursue a particular product candidate or indication and failing to capitalize on more profitable opportunities.
• Delays or difficulties in initiating or enrolling patients in clinical trials could delay or prevent necessary regulatory approvals.
• Positive results from early preclinical studies and clinical trials are not necessarily predictive of later-stage results, and failure to replicate these results would harm development.
• A pandemic, epidemic, or outbreak of an infectious disease may materially and adversely affect business and financial results, disrupting product candidate development.
• Current or future product candidates may cause adverse or undesirable side effects, potentially delaying or preventing regulatory approval, limiting commercial profile, or leading to negative consequences post-marketing.
• Even if regulatory approval is received, ongoing obligations and continued regulatory review may result in significant additional expense, labeling restrictions, market withdrawal, or penalties.
• Reliance on third parties to conduct preclinical studies and clinical trials poses risks if they fail to carry out duties, comply with regulations, or meet deadlines.
• Inability to obtain and maintain patent and other intellectual property protection, or insufficient scope of protection, could allow competitors to develop similar products and impair commercialization.
• Unstable global economic and geopolitical conditions may have serious adverse consequences on business, financial condition, stock price, and results of operations.
• Increased costs and management time will be incurred due to operating as a public company and new compliance initiatives.
• Adverse developments affecting the financial services industry could impact access to cash, cash equivalents, and marketable securities.
• Interim, topline, and preliminary data from clinical trials are subject to change and may not be consistent with final data.
• The incidence and prevalence for target patient populations of product candidates have not been established with precision, potentially leading to smaller market opportunities than estimated.
• Manufacturing is complex and relies on a limited number of third-party suppliers, and the loss of any of these suppliers could significantly harm the business.
• Failure to obtain, or delays in obtaining, required regulatory approvals for product candidates would materially impair the ability to generate revenue.
• Breakthrough Therapy Designation and/or Fast Track Designation, even if granted, may not lead to a faster development, regulatory review, or approval process.
• Seeking approval via the FDA's accelerated approval pathway may not lead to faster development or approval and does not increase the likelihood of marketing approval.
• Orphan Drug Designation may be unsuccessful or benefits may not be maintained, including the potential for market exclusivity.
• Inadequate funding for the FDA, SEC, and other government agencies could hinder their ability to review and approve regulatory submissions.
• Failure to receive marketing approval for product candidates outside the U.S. would limit market penetration and growth.
• The company is subject to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, with potential for serious consequences for violations.
• Unfavorable pricing regulations or third-party coverage and reimbursement policies could harm the business.
• Current and future healthcare legislative reform measures (e.g., ACA, IRA, OBBBA) may have a material adverse effect on business and results of operations, including drug pricing and reimbursement.
• Relationships with customers, healthcare providers, physicians, and third-party payors will be subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties.
• Employees, principal investigators, CROs, and consultants may engage in misconduct or other improper activities.
• Even if marketing approval is received, product candidates may not achieve broad market acceptance.
• Substantial competition exists from other companies developing drugs using protein degradation or traditional therapeutic modalities.
• Product liability lawsuits against the company could cause substantial liabilities and limit commercialization.
• Inability to establish sales and marketing and patient support capabilities or enter into agreements with third parties could prevent successful commercialization.
• Internal computer systems, or those of third-party contractors, may fail or suffer security breaches, disrupting development programs.
• Inability to adequately protect information systems from cyberattacks, security incidents, or compromises could result in disclosure of confidential information and reputational damage.
• Issues relating to the use of artificial intelligence and machine learning could adversely affect business and operating results.
• The price of common stock has been and may continue to be volatile, and investors may lose all or part of their investment.
• Executive officers, directors, principal stockholders, and their affiliates exercise significant influence over the company, limiting the ability to influence corporate matters and potentially delaying or preventing a change in corporate control.
• The issuance of a substantial number of warrants and equity awards could result in substantial dilution to existing stockholders.
• Sales of a substantial number of shares of common stock in the public market could cause the stock price to fall.
• No cash dividends are anticipated in the foreseeable future, making capital appreciation the sole source of gain for investors.
• The company may be at an increased risk of securities class action litigation.
• Changes in tax law may adversely affect the company or its investors.
• The ability to utilize net operating loss carryforwards and certain other tax attributes to offset future taxable income may be subject to limitations.
• Failure to maintain proper and effective internal control over financial reporting could harm operating results.
• Anti-takeover provisions under charter documents and Delaware law could delay or prevent a change of control.
• Amended and restated bylaws designate specific courts as the exclusive forum for certain litigation, which could limit stockholders' ability to obtain a favorable judicial forum.
• U.S. Congress or the current administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect the business.

Future Outlook

Kymera Therapeutics expects to advance at least one new molecular entity into clinical testing annually and intends to expand its therapeutic pipeline by identifying high-value targets. The company plans to build organizational capabilities to become a fully integrated biopharmaceutical company. Research and development expenses are projected to increase substantially with planned clinical development activities. Data from the KT-621 Phase 2b Atopic Dermatitis trial is expected by mid-2027, and from the KT-621 Phase 2b asthma trial by late-2027. Sanofi plans to advance the IRAK4 degrader KT-485/SAR447971 into clinical testing in 2026. The company anticipates continued impacts from inflationary pressures on the global economy, industry, and its operations, but believes its existing cash, cash equivalents, and marketable securities will fund operations into 2029.

Management Comments

• "We are a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of innovative, highly differentiated oral medicines that address significant health problems and meaningfully improve patients lives."
• "Our objective is to develop molecules that are both potent and highly selective, creating the unique potential to address diseases that are poorly served by current treatment options."
• "We believe we have the potential to deliver a compelling value proposition to a significant underserved patient population: small molecule medicines with biologics-like activity through the convenience of a daily, oral pill."
• "We expect to advance at least one new molecular entity into clinical testing annually."
• "We intend to leverage our drug development expertise to become a fully integrated biopharmaceutical company with an industry-leading pipeline of novel medicines."
• "We believe the existing cash, cash equivalents and marketable securities on hand will be sufficient to fund our operations into 2029."

Industry Context

StockSavvy.ai notes that Kymera Therapeutics is positioning itself as a leader in Targeted Protein Degradation (TPD), a next-generation small molecule therapeutic modality, aiming to address "undrugged" or "inadequately drugged" targets. This approach is highly innovative and seeks to overcome limitations of traditional small molecules and injectable biologics, which are often costly, inconvenient, and only treat symptoms. The focus on immunology, particularly Type 2 inflammatory diseases, aligns with a significant unmet medical need, as a large percentage of diagnosed patients remain untreated or receive symptomatic relief. The company's strategy to develop oral small molecules with "biologics-like activity" could be highly disruptive in markets currently dominated by injectable biologics, offering a compelling value proposition in terms of patient convenience and potentially lower manufacturing costs. The entry into oncology with the Gilead collaboration for CDK2 also diversifies its pipeline into another high-value therapeutic area with significant unmet needs. The competitive landscape for TPD is intensifying, with several other companies and large pharmaceutical firms investing in this field, indicating both the promise and the competitive pressures of this modality.

Comparison to Industry Standards

• KT-621 Phase 1b AD trial results showed median TARC reduction of 74% in patients with high baseline TARC, which was "in line with published dupilumab results at week 4."
• KT-621 achieved median Eotaxin-3 reductions of 62-73%, which "numerically exceeded what has been reported with dupilumab in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) patients even at 52 weeks."
• KT-621 achieved median IgE reduction of 5-14%, which was "comparable to the reported dupilumab data at week 4."
• KT-621 demonstrated mean EASI score reductions of 62-63%, and for EASI and all other clinical endpoints measured, "achieved improvements that were in line with or in some cases numerically exceeded published data for dupilumab at week 4."
• KT-621 in AD patients with comorbid asthma achieved a median FeNO reduction of 56%, which "numerically exceeded published data for dupilumab at week 4 in asthma patients."
• KT-579 in preclinical efficacy models of lupus and RA was "generally more efficacious than clinically active or marketed small molecule inhibitors and injectable biologics, phenocopying IRF5 knockout studies."
• The company's TPD approach aims to deliver "small molecule medicines with biologics-like activity," suggesting a goal to match or exceed the efficacy of biologics with the convenience of oral dosing.

Corporate Governance

Legal Proceedings

• Not currently a party to any litigation or legal proceedings that, in management's opinion, are likely to have a material adverse effect on the business.
• In August 2021, the company initiated a US patent office proceeding (post-grant review) to challenge a third-party patent unrelated to its current product candidates, which resulted in the owner of the challenged patent disclaiming it in full.

Related Party Transactions

• Jefferies LLC, with which Board member John Maraganore is affiliated, acted as an underwriter in both of the company's 2025 follow-on public offerings, receiving approximately $11.0 million in customary underwriting commissions.
• A Registration Rights Agreement was entered into on June 26, 2025, with Baker Brothers Life Sciences, L.P., 667, L.P. (BBA Funds), entities affiliated with Atlas Venture, and entities affiliated with BVF Partners L.P. (Affiliated Entities), all considered related parties due to affiliations with Board members. This agreement grants resale registration rights for approximately 29.7 million shares of common stock, exercisable starting February 28, 2026.
• An Open Market Sale Agreement with Jefferies LLC was entered into on October 31, 2024, for at-the-market offerings up to $300.0 million, prior to Dr. Maraganore joining Jefferies. No sales have been made under this agreement as of December 31, 2025.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and the exercise of outstanding warrants and equity awards, and the stock price may remain volatile.
• Employees benefit from competitive compensation, benefits, and development plans, but the company's growth strategy will require effective management of increasing headcount.
• Patients may benefit from the development of innovative oral medicines for underserved diseases in immunology and oncology, offering potentially more convenient and effective treatment options.
• Collaborators like Sanofi and Gilead Sciences are key partners in advancing specific programs, with potential for milestone payments and royalties for the company.
• Suppliers and contract manufacturing organizations (CMOs) are critical for preclinical and clinical supply, and any disruptions could impact development timelines.
• Creditors are not significantly impacted as the company primarily relies on equity financing, but future debt could introduce new obligations.

Next Steps

• Advance KT-621 into two parallel Phase 2b trials for moderate to severe Atopic Dermatitis and asthma, with data expected by mid-2027 and late-2027, respectively.
• Continue the Phase 1 clinical trial for KT-579 in healthy volunteers.
• Sanofi plans to advance KT-485/SAR447971 (IRAK4 degrader) into clinical testing in 2026.
• Kymera will lead all research activities for the CDK2 program under the Gilead collaboration.
• Continue to identify high-value targets and expand the therapeutic pipeline.
• Continue to invest in capabilities to identify novel molecules and optimize drug candidates.
• Expand and protect proprietary know-how and intellectual property.
• Build organizational capabilities to become a fully integrated biopharmaceutical company.
• Consider synergistic collaboration opportunities.
• Identify and qualify additional manufacturers for API, drug product, and drug substance prior to NDA/MAA submissions.
• Sublease the currently unoccupied 34,522 square feet of office and laboratory space in Watertown, Massachusetts.

Key Dates

Recommendation

Kymera Therapeutics presents a compelling long-term growth story in the innovative TPD space, evidenced by strong early clinical data for KT-621 and promising preclinical results for KT-579, alongside strategic collaborations with major pharmaceutical players like Sanofi and Gilead. The substantial cash runway into 2029 provides financial stability for continued R&D. However, the company remains in a high-risk, clinical-stage phase with no approved products and significant accumulated losses. The discontinuation of KT-474 and KT-295 highlights the inherent risks of drug development. While the potential is high, the path to profitability is long and uncertain, warranting a "Hold" recommendation for seasoned investors who are comfortable with high-risk, high-reward biotech investments and are willing to await further clinical milestones and regulatory clarity.

Keywords

Targeted Protein Degradation, Biopharmaceutical, Immunology, Oncology, STAT6, IRF5, IRAK4, CDK2, Atopic Dermatitis, Asthma, Lupus, Rheumatoid Arthritis, Clinical Trials, Drug Development, SEC Filing, 10-K, Biotechnology, Pharmaceutical, Preclinical, Phase 1, Phase 2b, Molecular Glue Degraders, Sanofi, Gilead Sciences, Financial Results, Risk Factors, Intellectual Property, Regulatory Approval